Health Care · Surgical & Medical Instruments & Apparatus · Nasdaq · CIK 2046386 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $40.51Day +2.04%Mkt cap $32.8BOff 52W high −20.4%Vol (1Y) 42.5%
Daily closing price, split-adjusted to the current basis; 0.6y shown of 142 bars on file. Sampled to 142 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest3.6% of sh out |
| Days to cover4.5d |
| 13F net flow (QoQ)+5.99% |
| Top-10 13F concentration67.2% |
| Next report (est.)2026-09-23 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$28.43B |
| Earnings (TTM)$1.16B |
| Net margin4.1% |
| Debt / equity1.17× |
| Total debt / EBITDA3.90× |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−3.5% |
Total return through 2026-07-28 · series begins 2025-12-17. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)42.5% |
| Ann. volatility (3Y)42.5% |
| Sharpe (1Y)0.16 |
| Sharpe (3Y)0.16 |
| Max drawdown (1Y)−30.6% |
| Max drawdown (3Y)−30.6% |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Carlyle Group Inc. | 187.1M | $8.3B | 23.10% | −13.1% |
| H&F Corporate Investors X, Ltd. | 86.5M | $3.8B | 10.68% | −13.1% |
| FMR LLC | 36.6M | $1.6B | 4.51% | +38.7% |
| Capital Research Global Investors | 23.2M | $1.0B | 2.86% | +56.7% |
| Invesco Ltd. | 21.0M | $933M | 2.59% | +728.8% |
| BlackRock, Inc. | 16.9M | $753M | 2.09% | +47.0% |
| MORGAN STANLEY | 15.7M | $699M | 1.94% | +3.6% |
| VANGUARD CAPITAL MANAGEMENT LLC | 14.7M | $655M | 1.82% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-28 | 2026-05-06 | $0.16 | — | $7.35B | +10.7% |
| 2025-03-29 | — | — | — | $6.64B | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-09-23 is ESTIMATED from filing cadence (median gap 70d) — not company-confirmed.
US 93% · Non Us 7%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
